Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Farid Dharamsi

Emergency Medicine Dallas, TX Medical Doctor

NPI 1619107828 CMS profile 1064004

5201 Harry Hines Blvd, House Staff & Gme, Dallas, TX 75235

Open in the dashboard

General payments

$159,328

285 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Farid Dharamsi of Dallas, TX is reported in the CMS Open Payments database as having received $159,328 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,118 84
2024 General $51,489 72
2023 General $47,665 36
2022 General $11,747 40
2021 General $218 6
2020 General $374 20
2019 General $718 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Farid Dharamsi
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Farid Dharamsi were reported at $47,118. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Farid Dharamsi Emergency Medicine median Middle half National median
2019 $718 $51 $18–$128 $163
2020 $374 $29 $16–$99 $114
2021 $218 $40 $18–$124 $132
2022 $11,747 $49 $20–$134 $149
2023 $47,665 $51 $22–$142 $160
2024 $51,489 $52 $22–$150 $164
2025 $47,118 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $145,571 166 payments
  2. Allergan Inc. $11,911 38 payments
  3. LEO Pharma Inc. $330 16 payments
  4. Sun Pharmaceutical Industries Inc. $266 14 payments
  5. Galderma Laboratories, L.P. $264 5 payments
  6. Ortho Dermatologics, a division of Bausch Health US, LLC $234 13 payments
  7. Merz North America, Inc. $159 5 payments
  8. Lilly USA, LLC $130 4 payments
  9. Incyte Corporation $92 5 payments
  10. Celgene Corporation $75 4 payments
  11. Other $296 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $139,586 30 payments
  2. Travel and Lodging $10,447 32 payments
  3. Food and Beverage $9,276 221 payments
  4. Education $19 2 payments
Products named General payments · program years 2019–2025
  1. BOTOX $74,214 102 payments
  2. KYBELLA $1,950 1 payment
  3. ADBRY $310 15 payments
  4. DYSPORT $225 3 payments
  5. TALTZ $130 4 payments
  6. Absorica LD $129 8 payments
  7. DUOBRII $119 6 payments
  8. Winlevi $118 7 payments
  9. ILUMYA $114 5 payments
  10. SKYRIZI $110 6 payments
  11. Other $998 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record